Literature DB >> 29367709

Haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk soft tissue sarcomas: results of a single-center prospective trial.

Michael Merker1, Michael Torsten Meister1, Eva Rettinger1, Andrea Jarisch1, Jan Soerensen1, Andre Willasch1, Sabine Huenecke1, Claudia Cappel1, Melanie Bremm1, Emilia Salzmann-Manrique1, Thomas Krenn2, Claudia Rossig3, Bernhard Kremens4, Ewa Koscielniak5, Thomas Klingebiel1, Peter Bader6.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29367709     DOI： 10.1038/s41409-018-0088-6

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  6 in total

1.  No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy.

Authors:  Sebastian Johannes Schober; Erika Hallmen; Florian Reßle; Hendrik Gassmann; Carolin Prexler; Angela Wawer; Irene von Luettichau; Ruth Ladenstein; Bernarda Kazanowska; Gustaf Ljungman; Felix Niggli; Olli Lohi; Julia Hauer; Bernd Gruhn; Thomas Klingebiel; Peter Bader; Stefan Burdach; Peter Lang; Monika Sparber-Sauer; Ewa Koscielniak; Uwe Thiel
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

2.  Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience.

Authors:  Michael Merker; Michael Torsten Meister; Annekathrin Heinze; Andrea Jarisch; Jan Sörensen; Sabine Huenecke; Melanie Bremm; Claudia Cappel; Thomas Klingebiel; Peter Bader; Eva Rettinger
Journal:  Oncotarget       Date:  2019-10-22

3.  The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation.

Authors:  Annekathrin Heinze; Beatrice Grebe; Melanie Bremm; Sabine Huenecke; Tasleem Ah Munir; Lea Graafen; Jochen T Frueh; Michael Merker; Eva Rettinger; Jan Soerensen; Thomas Klingebiel; Peter Bader; Evelyn Ullrich; Claudia Cappel
Journal:  Front Immunol       Date:  2019-12-03       Impact factor: 7.561

Review 4.  Current and Future Treatment Strategies for Rhabdomyosarcoma.

Authors:  Celine Chen; Heathcliff Dorado Garcia; Monika Scheer; Anton G Henssen
Journal:  Front Oncol       Date:  2019-12-20       Impact factor: 6.244

5.  ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.

Authors:  Michael Merker; Juliane Wagner; Hermann Kreyenberg; Catrin Heim; Laura M Moser; Winfried S Wels; Halvard Bonig; Zoltán Ivics; Evelyn Ullrich; Thomas Klingebiel; Peter Bader; Eva Rettinger
Journal:  Front Immunol       Date:  2020-10-19       Impact factor: 7.561

6.  Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor.

Authors:  Leonie D H Gossel; Catrin Heim; Lisa-Marie Pfeffermann; Laura M Moser; Halvard B Bönig; Thomas E Klingebiel; Peter Bader; Winfried S Wels; Michael Merker; Eva Rettinger
Journal:  Cancers (Basel)       Date:  2021-03-22       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.